Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Effect of intervention on decision making of treatment for disease progression, prostate‐specific antigen biochemical failure and prostate cancer death

Bibliographic Data

ID19506801
AuthorsRex C-C Huang, Anssi Auvinen (0000-0003-1125-4818, Professor of Epidemiology Tampere School of Public Health University of Tampere Tampere Finland), Matti Hakama (Professor of Epidemiology Tampere School of Public Health University of Tampere Tampere Finland), Teuvo L J Tammela (0000-0002-3529-4649, Professor of Epidemiology, Department of Urology Tampere University Hospital and University of Tampere Tampere Finland), Martti Ala‐Opas (Professor of Urology, Department of Urology Helsinki University Hospital Helsinki Finland), Mikael Leppilahti (Professor of Surgery, Department of Surgery Seinäjoki Hospital Seinäjoki Finland), Timo Vornanen (Professor of Surgery, Department of Surgery Kymenlaakso Central Hospital Kotka Finland), Hsiu‐Hsi Chen (Professor of Biostatistics, Tampere School of Public Health University of Tampere Tampere Finland, corresponding author)
Year2014
Volume17
Issue6
Pages776-783
Publication date2014-12-01
Open AccessYes
TypeARTICLE
VenueHealth Expectations (JOURNAL)
Journal identifiersISSN: 1369-6513 • E-ISSN: 1369-7625
PublisherWiley (PUBLISHER • GB)
DOI10.1111/j.1369-7625.2012.00802.x
PMID22809163
OpenAlexW1963972141
LanguageEN
Citations received1
References cited12

BACKGROUND: Patient preference for the choice of treatment modality for prostate cancer has increasingly gained attention. OBJECTIVE: To assess the impact of client-oriented decision on long-term mortality, disease progression and biochemical failure compared with standard treatment protocol (TP). METHODS: With data from a Finnish multicentre, randomized controlled trial with two arms [104 in the enhanced patient participation (EPP) arm and 106 in the TP arm], disease-specific and disease-free survival, biochemical failure with elevated prostate-specific antigen (PSA) level and disease progression were compared between the two arms using Wilcoxon test and also Cox proportional hazards regression model. RESULTS: Patients in the EPP arm had a higher risk of death by 37% [HR, 1.37 (0.87-2.17)] compared with those in the TP arm. Patients in the EPP arm were at increased risk of having biochemical failure by 14% [HR, 1.14 (0.72-1.79)] and for having disease progression by 2% [HR, 1.02 (0.61-1.70)] compared with those in the TP arm. All the differences were non-significant. CONCLUSIONS: Patients actively involved in the choice of treatment had higher risk of prostate cancer death but only slightly increased risk of biochemical failure and clinical disease progression. These findings would provide a good reference when patient autonomy for the choice of treatment modality is addressed

Cancer · Disease · Proportional hazards model · Prostate · Prostate cancer · Prostate-specific antigen · Randomized controlled trial · Medicine · Patient-Provider Communication in Healthcare · Prostate Cancer Diagnosis and Treatment · Prostate Cancer Treatment and Research · Internal Medicine · Oncology

  • Decision aids for people facing health treatment or screening decisions

    Dawn Stacey, France Légaré et al.•Cochrane Database of Systematic…•2017

Citations per year0.11
Citation span2017 - 2017 (1)
Highly citedNo

Tools

Open DOISci-HubOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae